Thomas Gad - 16 Nov 2021 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role: Chairman, President and Head of Business Development & Strategy, Director
Signature: /s/ THOMAS GAD
Issuer symbol: YMAB
Transactions as of: 16 Nov 2021
Transactions value $: -$77,302
Form type: 4
Filing time: 18 Nov 2021, 16:18:39 UTC
Previous filing: 01 Nov 2021
Next filing: 26 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	YMAB	Common Stock	Sale	-$77,302	-4,000	-0.27%	$19.33	1,484,927	16 Nov 2021	By GAD Enterprises LLC	F1, F2, F3
holding	YMAB	Common Stock						50,000	16 Nov 2021	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2021.
F2	This transaction was executed in multiple trades at prices ranging from $18.75 to $20.62. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3	Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.

Remarks:

Chairman, President and Head of Business Development & Strategy